Quetiapine

Generic Name: Quetiapine

Brand Names: Seroquel

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₅N_₃O_₂S

CAS Number: 111974-69-7

Unique Ingredient Identifier: BGL0JSY5SI

Background: Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivi...

Indication: Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in comb...

Associated Conditions: Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode

Associated Therapies: -

Clinical Trials

Effect of Quetiapine on Marijuana Withdrawal and Relapse

Phase 2

Completed

Conditions: Marijuana Smoking

Interventions: Drug: Marijuana
Drug: Placebo oral capsule
Drug: Quetiapine

First Posted Date: 2008-08-28

Last Posted Date: 2017-08-18

Lead Sponsor: New York State Psychiatric Institute

Target Recruit Count: 20

Registration Number: NCT00743366

Locations: 🇺🇸
New York State Psychiatric Institute, New York, New York, United States

Efficacy of Bifeprunox in Patients With Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Bifeprunox
Drug: Placebo
Drug: Quetiapine

First Posted Date: 2008-06-25

Last Posted Date: 2010-09-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 346

Registration Number: NCT00704509

Locations: 🇮🇳
IN006, Chennai, India
🇮🇳
IN008, Ahmedabad, India
🇮🇳
IN011, Ahmedabad, India

and more 42 locations

Quetiapine in Co-Morbid Depressive and Anxiety Disorders

Not Applicable

Completed

Conditions: Post-traumatic Stress Disorder
Dysthymic Disorder
Major Depressive Disorder
Anxiety Disorders
Generalized Anxiety Disorder
Social Anxiety Disorder
Panic Disorder

Interventions: Drug: Placebo
Drug: Quetiapine

First Posted Date: 2008-06-03

Last Posted Date: 2014-08-21

Lead Sponsor: Centre for Addiction and Mental Health

Target Recruit Count: 108

Registration Number: NCT00688818

Locations: 🇨🇦
Centre for Neuropsychiatric Study, Markham, Ontario, Canada
🇨🇦
Credit Valley Medical Arts Centre, Mississauga, Ontario, Canada
🇨🇦
Centre for Addiction and Mental Health, Toronto, Ontario, Canada

and more 1 locations

Quetiapine in Postpartum Depression

Phase 2

Terminated

Conditions: Postpartum Depressive Disorder

Interventions: Drug: Quetiapine

First Posted Date: 2008-05-21

Last Posted Date: 2010-12-21

Lead Sponsor: AstraZeneca

Target Recruit Count: 5

Registration Number: NCT00681668

Locations: 🇩🇪
Research Site, Herten, Westfalen-Lippe, Germany

Seroquel for Frequent, Heavy Drinkers

Phase 2

Completed

Conditions: Alcoholism

Interventions: Drug: Placebo
Drug: Seroquel

First Posted Date: 2008-05-08

Last Posted Date: 2014-09-17

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 156

Registration Number: NCT00674765

Locations: 🇺🇸
University of Pennsylvania, Treatment Research Center, Philadelphia, Pennsylvania, United States

Anxiety in Recovering Opiate Dependence

Phase 4

Terminated

Conditions: Generalized Anxiety Disorder
Comorbid Opiate Dependence in Remission
Status Post Methadone-Maintenance Treatment

Interventions: Drug: Quetiapine

First Posted Date: 2008-04-29

Last Posted Date: 2013-02-18

Lead Sponsor: Beth Israel Medical Center

Target Recruit Count: 14

Registration Number: NCT00668265

Locations: 🇺🇸
Su Casa Methadone-to-Abstinence Rehabilitation, New York, New York, United States

Study in Schizophrenic In-patients Treated With Quetiapine Prolong or Oral Risperidone at Flexible Dose

Phase 3

Terminated

Conditions: Schizophrenic Disorders

Interventions: Drug: Quetiapine
Drug: Risperidone

First Posted Date: 2008-04-17

Last Posted Date: 2010-09-17

Lead Sponsor: AstraZeneca

Target Recruit Count: 29

Registration Number: NCT00660595

Locations: 🇫🇮
Research Site, Turku, Finland

Efficacy of Bifeprunox in Patients With Schizophrenia

Phase 3

Terminated

Conditions: Schizophrenia

Interventions: Drug: Placebo
Drug: Quetiapine
Drug: Bifeprunox

First Posted Date: 2008-04-15

Last Posted Date: 2010-09-27

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 227

Registration Number: NCT00658645

Locations: 🇷🇺
RU017, Chita, Russian Federation
🇷🇺
RU005, Moscow, Russian Federation
🇷🇴
RO002, Bucuresti, Romania

and more 35 locations

Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

Phase 3

Completed

Conditions: Cognition
Schizophrenia

Interventions: Drug: Quetiapine
Drug: Sertindole

First Posted Date: 2008-04-09

Last Posted Date: 2014-05-28

Lead Sponsor: H. Lundbeck A/S

Target Recruit Count: 264

Registration Number: NCT00654706

Locations: 🇺🇸
US012, Baltimore, Maryland, United States
🇺🇸
US020, Dallas, Texas, United States
🇺🇸
US014, Stanford, California, United States

and more 23 locations

Effect of Quetiapine on Sleep Architecture in Bipolar Depression and Major Depressive Disorder

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Seroquel

First Posted Date: 2008-02-15

Last Posted Date: 2015-12-16

Lead Sponsor: Queen's University

Target Recruit Count: 15

Registration Number: NCT00616889

Locations: 🇨🇦
Pccc, Mhs, Kingston, Ontario, Canada

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy